Ex vivo non-viral vector-mediated neurotrophin-3	1
Ex vivo	1
non-viral vector-mediated neurotrophin-3	9
gene	50
transfer to olfactory ensheathing glia : effects on axonal regeneration	55
transfer to olfactory ensheathing glia	55
transfer	55
olfactory ensheathing glia	67
effects on axonal regeneration	95
effects	95
axonal regeneration	106
functional recovery after implantation in rats with spinal cord injury Jun	130
functional recovery	130
implantation in rats with spinal cord injury Jun	156
implantation	156
rats with spinal cord injury Jun	172
rats	172
spinal cord injury Jun	182
WU , Tian-Sheng SUN , Ji-Xin REN , Xian-Zhang WANG Abstract	206
WU	206
Tian-Sheng SUN	210
Ji-Xin REN	226
Xian-Zhang WANG Abstract	238
Objective	265
olfactory ensheathing glia -LRB- OEG -RRB- implantation	283
OEG	311
ex vivo non-viral vector-based neurotrophin - 3 -LRB- NT-3 -RRB- gene therapy	334
ex vivo non-viral vector-based neurotrophin	334
ex vivo	334
non-viral vector-based neurotrophin	342
3 -LRB- NT-3 -RRB- gene therapy	379
3 -LRB- NT-3 -RRB-	379
gene therapy	388
regeneration	426
thoracic spinal cord injury -LRB- SCI -RRB-	445
thoracic spinal cord injury	445
SCI	474
Methods Primary OEG	480
cationic liposome-mediated recombinant plasmid pcDNA3 .1	522
+	578
- NT3 and subsequently implanted into adult Wistar rats	580
NT3	581
adult Wistar rats	617
the thoracic spinal cord -LRB- T9 -RRB- contusion	650
the New York University impactor	693
The animals in 3 different groups	727
The animals	727
3 different groups	742
4 × 105 OEG transfected with pcDNA3 .1	770
4 × 105 OEG	770
4 ×	770
105 OEG	772
pcDNA3 .1	797
+	806
NT3	809
pcDNA3 .1	816
+	825
plasmids , or the OEGs	828
plasmids	828
the OEGs	841
any plasmid	858
transfection , respectively ; the fourth group	870
transfection , respectively	870
transfection	870
the fourth group	898
untreated group , in	919
untreated group	919
no OEG	945
Results NT-3 production was seen	967
Results	967
NT-3 production	975
both ex vivo	1010
pcDNA3 .1 -LRB- + -RRB-	1038
pcDNA3 .1	1038
+	1047
NT3 transfected OEGs	1050
NT3	1050
OEGs	1066
Three months	1072
implantation of NT-3-transfected OEGs	1091
implantation	1091
NT-3-transfected OEGs	1107
behavioral analysis	1130
the hindlimb function of SCI rats	1164
the hindlimb function	1164
SCI rats	1189
All spinal cords	1212
neurofilament-positive axons	1258
Retrograde tracing	1288
Retrograde	1288
Conclusion Non-viral vector-mediated genetic engineering of OEG	1356
Conclusion Non-viral vector-mediated genetic engineering	1356
OEG	1416
NT - 3	1461
NT	1461
3	1465
axonal outgrowth	1481
SCI recovery	1520
rats	1536
1 Introduction Impairment	1543
motor and sensory function following spinal cord injury -LRB- SCI -RRB-	1572
motor and sensory function	1572
spinal cord injury -LRB- SCI -RRB-	1609
spinal cord injury	1609
SCI	1629
disruption of descending motor pathways and ascending sensory ones	1657
disruption	1657
motor pathways	1682
sensory ones	1711
SCI	1731
very little regenerative response	1736
the adult mammalian central nervous system -LRB- CNS -RRB-	1780
the adult mammalian central nervous system	1780
CNS	1824
permanent loss of function and paralysis	1841
permanent loss	1841
function and paralysis	1859
There	1883
no available therapy for restoration of function at present	1892
no available therapy	1892
restoration of function at present	1917
restoration	1917
function at present	1932
function	1932
Many investigators	1953
strategies	1988
the restoration of function	2003
the restoration	2003
function	2022
SCI	2046
cellular transplantation	2055
a promising strategy -LSB- 1-3 -RSB-	2095
a promising strategy	2095
1-3 -RSB-	2116
Both normal and transected olfactory axons	2122
normal	2127
transected olfactory axons	2138
the unusual property	2170
adult CNS , find their appropriate targets ,	2218
adult CNS	2218
their appropriate targets	2234
synaptic contacts	2270
them	2293
4 -RSB-	2298
A critical element	2302
the ability of olfactory axons to regenerate and form specific connections	2324
the ability	2324
olfactory axons	2339
specific connections	2378
the presence	2402
a unique supporting cell , the olfactory ensheathing glia -LRB- OEG -RRB-	2418
a unique supporting cell	2418
the olfactory ensheathing glia -LRB- OEG -RRB-	2444
the olfactory ensheathing glia	2444
OEG	2476
These cells uniquely present	2482
These cells	2482
Schwann cell-like and astrocyte-like characteristics	2516
5 -RSB-	2569
great potential	2589
damaged spinal cord -LSB- 2,5-9 -RSB-	2615
damaged spinal cord	2615
2,5-9 -RSB-	2635
not all axonal populations	2652
OEG implants -LSB- 10 -RSB-	2689
OEG implants	2689
10 -RSB-	2702
Additional vector-mediated neurotrophin	2707
their regeneration-supporting properties	2771
endogenous neurotrophic factor expressed by OEG	2821
endogenous neurotrophic factor	2821
OEG	2865
11,12 -RSB-	2876
Neurotrophins	2884
their beneficial effects	2917
neurite outgrowth and neuroprotection	2945
Neurotrophin-3 -LRB- NT-3 -RRB-	2984
Neurotrophin-3	2984
NT-3	3000
one of important factors in regenerative milieu	3009
one	3009
important factors in regenerative milieu	3016
important factors	3016
regenerative milieu	3037
variety of physiological effects	3068
variety	3068
physiological effects	3079
nervous system development -LSB- 13 -RSB-	3104
nervous system development	3104
13 -RSB-	3131
Many studies	3136
the usage of NT-3 stimulating nerve regeneration	3164
the usage	3164
NT-3 stimulating nerve regeneration	3177
the safe and efficient delivery of NT-3 to the site of injury	3218
the safe and efficient delivery	3218
NT-3 to the site of injury	3253
NT-3	3253
the site of injury	3261
the site	3261
injury	3273
its short half-life and the barrier between brain and vessel	3312
its short half-life	3312
the barrier between brain and vessel	3336
the barrier	3336
brain and vessel	3356
Gene transfer technique	3374
a new strategy	3407
application of NT-3	3426
application	3426
NT-3	3441
insertion of NT-3 gene	3457
insertion	3457
NT-3 gene	3470
OEG	3485
NT-3	3515
the physiological action	3543
The present experiment	3569
SCI	3628
ex vivo	3644
plasmid-transfected OEG implants	3652
more conducive conditions for axonal regeneration	3709
more conducive conditions	3709
axonal regeneration	3739
We	3760
the effects of plasmid vector-mediated hypersecretion of NT-3	3772
the effects	3772
plasmid vector-mediated hypersecretion of NT-3	3787
plasmid vector-mediated hypersecretion	3787
NT-3	3829
functional recovery and axonal regeneration	3837
functional recovery	3837
axonal regeneration	3861
thoracic injury	3887
Anatomical and functional analyses	3904
regeneration	3959
animals over a 12-week observation period	3975
animals	3975
a 12-week observation period	3988
2 Materials and methods 2.1 Recombinant plasmid pcDNA3	4019
2 Materials	4019
methods 2.1 Recombinant plasmid pcDNA3	4035
methods	4035
2.1 Recombinant plasmid pcDNA3	4043
+	4076
NT3 production Coding sequence	4079
NT-3	4113
PCR	4135
gene got from rat liver cells	4144
gene	4144
rat liver cells	4158
pcDNA3 .1 -LRB- + -RRB-	4190
pcDNA3 .1	4190
+	4199
eukaryotic expression vector	4202
Analysis by restricting enzyme digestion and DNA sequencing	4232
Analysis	4232
enzyme digestion and DNA sequencing	4256
enzyme digestion	4256
DNA sequencing	4277
the sequence of plasmid	4324
the sequence	4324
plasmid	4340
14 -RSB-	4372
2.2 Culturing of OEG The isolation of OEG from the olfactory bulb nerve layer	4377
2.2 Culturing	4377
OEG The isolation of OEG from the olfactory bulb nerve layer	4394
The isolation of OEG from the olfactory bulb nerve layer	4398
The isolation	4398
OEG from the olfactory bulb nerve layer	4415
OEG	4415
the olfactory bulb nerve layer	4424
15 -RSB-	4486
newborn Wistar rats	4500
intraperitoneal injection of a lethal dose of pentobarbital	4535
intraperitoneal injection	4535
a lethal dose of pentobarbital	4564
a lethal dose	4564
A craniotomy	4612
sterile conditions	4653
the olfactory bulb	4682
The olfactory bulb	4702
a Petri dish with ice cold HBSS -LRB- Hanks balanced salt solution -RRB-	4760
a Petri dish	4760
ice cold HBSS -LRB- Hanks balanced salt solution -RRB-	4778
ice cold HBSS	4778
Hanks balanced salt solution	4793
Hanks	4793
balanced salt solution	4799
The bulbs	4824
ice cold HBSS	4857
a sterile scalpel blade	4892
The minced bulb tissue	4917
5 mL of HBSS	4962
5 mL	4962
HBSS	4970
1 mg/mL trypsin	4980
37 °C for 15 min	5013
37 °C	5013
15 min	5023
continual shaking	5035
DMEM -LRB- Sigma -RRB-	5054
DMEM	5054
Sigma	5060
Ham 's F-12 -LRB- DMEM / F-12 ; 1:1 mixture ; Sigma -RRB-	5071
Ham 's F-12	5071
Ham 's	5071
DMEM	5083
F-12 ; 1:1 mixture ; Sigma	5089
F-12	5089
1:1 mixture ; Sigma	5095
1:1 mixture	5095
Sigma	5108
10 % fetal bovine serum -LRB- DF-10S ; Invitrogen -RRB-	5133
10 % fetal bovine serum	5133
DF-10S ; Invitrogen	5157
DF-10S	5157
Invitrogen	5165
the trypsinization	5195
the specimen	5218
The supernatant	5256
the cells	5290
DF-10S	5326
DF-10S culture medium	5334
L-glutamine -LRB- 20 mmol/L -RRB-	5374
L-glutamine	5374
20 mmol/L	5387
penicillin/streptomycin -LRB- 10 000 μg/mL -RRB-	5403
penicillin/streptomycin	5403
10 000 μg/mL	5428
10	5428
000 μg/mL	5431
the cells	5456
a 70-μm mesh filter	5481
An aliquot of cells	5502
An aliquot	5502
cells	5516
viability	5538
0.1 % trypan blue	5553
cells	5575
a hemocytometer	5599
The cell suspension	5616
1 × 106 cells/mL	5651
1 ×	5651
106 cells/mL	5653
25 cm2 flask pretreated with poly-D-lysin -LRB- 0.2 mg/mL -RRB-	5682
25 cm2 flask	5682
poly-D-lysin -LRB- 0.2 mg/mL -RRB-	5711
poly-D-lysin	5711
0.2 mg/mL	5725
Cells	5737
7 d	5762
37 oC with 5 % CO2	5769
37 oC	5769
5 % CO2	5780
culture medium	5793
every 2 d. Six days following the plating	5816
every 2 d.	5816
Six days	5827
the plating	5846
OEGs	5859
contaminated cells	5883
the serum-free medium -LRB- SFM -RRB- instead of DF-10S	5911
the serum-free medium -LRB- SFM -RRB-	5911
the serum-free medium	5911
SFM	5934
DF-10S	5950
The SFM	5958
DMEM	5979
biotin -LRB- 10 ng/mL -RRB-	5985
biotin	5985
10 ng/mL	5993
insulin -LRB- 5 g/mL -RRB-	6004
insulin	6004
5 g/mL	6013
transferrin -LRB- 50 g/mL -RRB-	6024
transferrin	6024
50 g/mL	6037
sodium selenate -LRB- 5.2 ng/mL -RRB-	6049
sodium selenate	6049
5.2 ng/mL	6066
hydrocortisone -LRB- 10 ng/mL -RRB-	6078
hydrocortisone	6078
10 ng/mL	6094
glutamine -LRB- 292 mg/L -RRB-	6108
glutamine	6108
292 mg/L	6119
cells	6144
37 °C with 5 % CO2	6168
37 °C	6168
5 % CO2	6179
culture medium	6191
every 3 d. 2.3 Transfection	6214
OEG cultures	6245
cationic liposome	6263
We	6281
Lipofectamine2000 -LRB- Invitrogen -RRB-	6289
Lipofectamine2000	6289
Invitrogen	6308
the media	6323
the plasmids	6345
OEG	6363
Transfection procedure	6368
the instructions of manufacturer	6418
the instructions	6418
manufacturer	6438
one day	6461
transfection	6476
cells	6490
growth medium -LRB- without antibiotics -RRB- in a 24-well plate	6511
growth medium -LRB- without antibiotics -RRB-	6511
growth medium	6511
antibiotics	6534
a 24-well plate	6550
they	6574
90 % -95 % confluent	6588
90 %	6588
-95 %	6591
the time of transfection	6609
the time	6609
transfection	6621
plasmid	6642
50 μL of Opti-MEM	6653
50 μL	6653
Opti-MEM	6662
I	6671
Serum Medium	6681
serum and mix	6702
Lipofectamine2000	6728
use	6760
the appropriate amount in 50 μL of Opti-MEM	6777
the appropriate amount	6777
50 μL of Opti-MEM	6803
50 μL	6803
Opti-MEM	6812
I Medium	6821
5 min at room temperature	6859
5 min	6859
room temperature	6868
the 5-min incubation	6892
the diluted DNA with the diluted Lipofectamine2000	6922
the diluted DNA	6922
the diluted Lipofectamine2000	6943
20 min at room temperature	7002
20 min	7002
room temperature	7012
the formation of plasmid	7038
the formation	7038
plasmid	7055
Lipofectamine2000 complexes	7064
the complexes	7097
each well	7114
each	7114
the plate	7147
the cells	7182
37 °C in a CO2 incubator for 24-48 h	7195
37 °C	7195
a CO2 incubator for 24-48 h	7204
a CO2 incubator	7204
24-48 h	7224
they	7238
assay for transgene expression	7257
assay	7257
transgene expression	7267
2.4 NT-3 production	7289
transfected OEG	7314
The NT-3 levels	7330
secreted plasmid in conditioned medium from transfected OEG cultures	7349
secreted plasmid	7349
conditioned medium from transfected OEG cultures	7369
conditioned medium	7369
transfected OEG cultures	7393
ELISA	7437
Woodhall et al. -LSB- 12 -RSB-	7460
Woodhall et al. -LSB-	7460
The medium	7481
3 d	7506
the cultures	7532
24 h for determination of the production per day	7559
24 h	7559
determination of the production per day	7568
determination	7568
the production per day	7585
the production	7585
day	7604
The Emax immunoassay system -LRB- Promega -RRB-	7609
The Emax immunoassay system	7609
Promega	7638
the NT-3 levels	7666
OEG conditioned medium	7685
The amount of NT-3 secreted from 1 × 105 transfected cells per day	7709
The amount	7709
NT-3 secreted from 1 × 105 transfected cells per day	7723
NT-3	7723
1 ×	7742
105 transfected cells per day	7744
105	7744
cells per day	7760
cells	7760
day	7770
2.5 Biological activity of plasmid vector-derived NT-3	7788
2.5 Biological activity	7788
plasmid vector-derived NT-3	7815
recombinant NT-3 protein	7864
we	7914
their effects	7925
the neurite outgrowth	7942
human neuroblastoma cells	7967
Primary human neuroblastoma cells	7994
The attached cells	8067
0.05 % trypsin -LRB- Invitrogen -RRB- for 10 min	8106
0.05 % trypsin -LRB- Invitrogen -RRB-	8106
0.05 % trypsin	8106
Invitrogen	8121
10 min	8137
the reaction	8154
DMEM -LRB- Sigma -RRB-	8189
DMEM	8189
Sigma	8195
Ham 's F-12 -LRB- 1:1 ; Sigma -RRB-	8206
Ham 's F-12	8206
Ham 's	8206
1:1 ; Sigma	8218
1:1	8218
Sigma	8223
10 % fetal bovine serum -LRB- DF-10S ; Invitrogen -RRB-	8248
10 % fetal bovine serum	8248
DF-10S ; Invitrogen	8272
DF-10S	8272
Invitrogen	8280
The suspension	8293
serum-free medium	8328
4 plates	8362
a density of 1 ×	8374
a density	8374
1 ×	8387
104	8389
500 μL medium from the cultures of OEGs	8399
500 μL medium	8399
the cultures of OEGs	8418
the cultures	8418
OEGs	8434
pcDNA3	8456
+	8465
NT3	8468
pcDNA3 .1	8475
+	8484
OEGs without plasmid transfection	8491
OEGs	8491
plasmid transfection	8504
added to	8530
added	8530
3 different	8539
3	8539
plates	8551
The rest plate	8559
serum-free medium	8589
Three days later	8608
neurite outgrowth	8626
2.6 Preparation of OEG for spinal implantation OEG suspensions	8662
2.6 Preparation	8662
OEG for spinal implantation OEG suspensions	8681
OEG	8681
spinal implantation OEG suspensions	8689
Ruitenberg	8742
et al. described -LSB- 16 -RSB-	8753
et al.	8753
16 -RSB-	8770
OEGs	8784
poly-L-lysine-coated dishes	8806
a density of 1 ×	8837
a density	8837
1 ×	8850
106 cells in DF-10S	8852
106 cells	8852
DF-10S	8865
The next day	8873
the medium	8887
fresh medium	8916
pcDNA3	8940
+	8949
- NT3 or pcDNA3 .1 -LRB- + -RRB- , and cells	8951
- NT3 or pcDNA3 .1 -LRB- + -RRB-	8951
NT3	8952
pcDNA3 .1 -LRB- + -RRB-	8959
pcDNA3 .1	8959
cells	8976
72 h	8996
that	9008
the OEG cultures	9014
trypsinization	9073
serum-free DMEM/F -12 medium	9108
cells	9143
low-speed centrifugation	9166
appropriate volume of DMEM/F -12	9230
appropriate volume	9230
DMEM/F -12	9252
the OEG suspension	9272
50 000 / μL	9294
50 000	9294
μL	9302
The viability	9306
OEG suspensions	9323
the percentage of dead cells using Trypan blue staining	9371
the percentage	9371
dead cells using Trypan blue staining	9389
dead cells	9389
Trypan blue staining	9406
> 95 %	9432
>	9432
2.7 Experimental design Wistar rats -LRB- 200-240 g -RRB-	9438
2.7 Experimental design Wistar rats	9438
200-240 g	9475
standard conditions	9504
a 12/12 h light/dark cycle	9529
water and food ad libitum	9573
All experimental procedures	9600
accordance	9646
the guidelines of the local Animal Welfare Committee	9662
the guidelines	9662
the local Animal Welfare Committee	9680
use and care of laboratory animals	9719
use and care	9719
laboratory animals	9735
Forty four adult female rats	9755
the thoracic spinal cord contusion	9802
four groups	9859
group 1 -LRB- n = 10 -RRB-	9872
group 1	9872
n	9881
10	9884
implantation	9922
groups 2 and 3	9936
implantation of untransfected OEG -LRB- n = 10 -RRB-	9960
implantation	9960
untransfected OEG -LRB- n = 10 -RRB-	9976
untransfected OEG	9976
n	9995
10	9999
pcDNA3 .1	10006
+	10015
OEG -LRB- n = 12 -RRB- , respectively ; and group 4 -LRB- n = 12 -RRB-	10030
OEG -LRB- n = 12 -RRB- , respectively	10030
OEG -LRB- n = 12 -RRB-	10030
OEG	10030
n	10035
12	10039
group 4 -LRB- n = 12 -RRB-	10062
group 4	10062
n	10071
12	10075
implantation of pcDNA3 .1	10088
implantation	10088
pcDNA3 .1	10104
NT3-transfected OEG	10116
The recovery of rats ' hindlimb performance	10137
The recovery	10137
rats ' hindlimb performance	10153
rats '	10153
12 weeks	10205
Seven days	10215
implantation , two animals	10232
implantation	10232
two animals	10246
each group	10258
evaluation of transgene expression	10284
evaluation	10284
transgene expression	10298
Fourteen days	10320
another two rats from each group	10355
another two rats	10355
each group	10377
fluorochrome -LRB- FG ; Vector Laboratories -RRB-	10419
fluorochrome	10419
FG ; Vector Laboratories	10433
FG	10433
Vector Laboratories	10437
2.8 Surgical procedures	10459
OEG into complete thoracic transection injury model	10499
OEG	10499
complete thoracic transection injury model	10508
detail -LSB- 16 -RSB-	10579
detail	10579
16 -RSB-	10586
brief	10594
animals	10601
laminectomy	10641
T9-T10	10656
they	10673
a 25 g/cm	10694
spinal cord contusion using the New York University impactor -LSB- 17 -RSB-	10704
spinal cord contusion	10704
the New York University impactor -LSB- 17 -RSB-	10732
the New York University impactor	10732
17 -RSB-	10765
a technically complete injury	10775
the OEG	10820
the middle of spinal cord	10857
the middle	10857
spinal cord	10871
1 mm distance , both proximal and distal ,	10886
1 mm distance	10886
the edges of the lesion area	10932
the edges	10932
the lesion area	10945
dorsal	10978
cells	10986
the following four sites of each cord stump	11011
the following four sites	11011
each cord stump	11039
ventral	11060
funiculus ,	11068
funiculus	11068
gray	11083
commissure ,	11088
commissure	11088
-LRB- 3 -RRB- dorsal corticospinal tract , and -LRB- 4 -RRB-	11100
-LRB- 3 -RRB- dorsal corticospinal tract	11100
dorsal	11104
tract	11125
-LRB- 4 -RRB-	11136
fasciculus	11148
Coordinates of the four injection sites	11160
Coordinates	11160
the four injection sites	11175
1.75 mm , 1.25 mm , 1 mm , and 0.5 mm	11205
1.75 mm	11205
1.25 mm	11214
1 mm	11223
0.5 mm	11233
Each site	11255
1 L of a suspension containing 5 × 104 cells	11274
1 L	11274
a suspension containing 5 × 104 cells	11283
a suspension	11283
5 × 104 cells	11307
5 ×	11307
104 cells	11309
we	11329
total 2 × 105 cells into each cord stump	11341
total 2 × 105 cells	11341
each cord stump	11364
Injections	11381
a sterile glass micropipette , Hamilton syringe , and a micromanipulator	11413
a sterile glass micropipette	11413
Hamilton syringe	11443
a micromanipulator	11465
All animals	11485
a postoperative subcutaneous injection of 2 mL physiological salt solution	11506
a postoperative subcutaneous injection	11506
2 mL physiological salt solution	11548
2 mL	11548
blood loss	11599
their bladders	11615
reflexes	11663
The rats	11682
pairs in separate cages	11710
pairs	11710
separate cages	11719
the end of surgical procedures	11738
the end	11738
surgical procedures	11749
the viability of OEG suspensions used for implantation	11770
the viability	11770
OEG suspensions used for implantation	11787
OEG suspensions	11787
implantation	11812
between 90 % and 95 %	11838
determined by Trypan blue staining	11861
Trypan	11875
2.9 In vivo transgene expression RT-PCR	11897
2.9 In vivo transgene expression	11897
2.9	11897
In vivo transgene expression	11901
RT-PCR	11930
7 d	11951
implantation	11961
transgene expression	11986
total cellular mRNA	12017
the injury area	12055
Test Kit following the manufacturer 's instructions	12080
Test Kit	12080
the manufacturer 's instructions	12099
the manufacturer 's	12099
The resulting cDNA	12132
PCR	12168
PCR reaction	12173
25 μL volume containing	12203
25 μL volume	12203
2 μL	12228
cDNA , 2 U of Taq polymerase , 2 μL primers -LRB- forward and reverse -RRB-	12236
cDNA	12236
2 U of Taq polymerase , 2 μL primers -LRB- forward and reverse -RRB-	12242
2 U of Taq polymerase	12242
2 U	12242
Taq polymerase	12249
2 μL primers -LRB- forward and reverse -RRB-	12265
2 μL primers	12265
3 μL beta-actin -LRB- inner reference -RRB-	12305
3 μL beta-actin	12305
inner reference	12322
Reaction conditions	12340
94 °C for 10 min	12368
94 °C	12368
10 min	12378
94 °C for 1 min	12394
94 °C	12394
1 min	12404
55 °C	12414
1 min	12424
72 °C for 1 min	12438
72 °C	12438
1 min	12448
35 cycles ; followed by a final extension at 72 °C for 10 min	12459
35 cycles	12459
a final extension	12482
72 °C for 10 min	12503
72 °C	12503
10 min	12513
2.10 Locomotor analysis	12521
surgery	12551
animals	12560
an open field environment on 1 , 14 , 28 , 42 , 56 , and 84 d post-operation	12587
an open field environment	12587
1 , 14 , 28 , 42 , 56 , and 84 d post-operation	12616
1	12616
14	12619
28	12623
42	12627
56	12631
84 d post-operation	12639
Videotapes	12660
a blinded scorer	12688
the Basso Beattie Bresnahan -LRB- BBB -RRB- scores -LSB- 18 -RSB-	12710
Basso Beattie Bresnahan -LRB- BBB -RRB- scores	12714
BBB	12739
each animal at each testing session	12773
each animal	12773
each testing session	12788
Scores from the left and right side	12810
Scores	12810
the left and right side	12822
a single score	12864
each animal at each testing session	12897
each animal	12897
each testing session	12912
2.11 Retrograde axon tracing The regenerated axons	12934
2.11 Retrograde axon	12934
The regenerated axons	12963
FG	13014
a neuronal label , 14 d before perfusion	13021
a neuronal label	13021
14 d before perfusion	13039
14 d	13039
perfusion	13051
brief	13065
the animals	13072
a stereotaxic frame for laminectomy	13097
a stereotaxic frame	13097
laminectomy	13121
deep ketamine -- xylazine anesthesia	13139
deep ketamine	13139
xylazine anesthesia	13153
FG tracer in glass pipettes	13174
FG tracer	13174
glass pipettes	13187
the spinal cord caudad	13232
the lesion region	13258
The injector	13277
place	13302
5 min	13312
careful withdrawal of the glass capillary and suturing of the skin	13331
careful withdrawal of the glass capillary	13331
careful withdrawal	13331
the glass capillary	13353
suturing of the skin	13377
suturing	13377
the skin	13389
2.12 Histological analysis Rats	13399
12 weeks	13447
the spinal cords	13476
immunohistochemical staining of neurofilament -LRB- NF -RRB-	13512
immunohistochemical staining	13512
neurofilament -LRB- NF -RRB-	13544
neurofilament	13544
NF	13559
brief	13567
the anesthetized rats	13574
cold PBS -LRB- 0.1 mol/L , pH 7.2 -RRB-	13615
cold PBS	13615
0.1 mol/L	13625
pH 7.2	13636
heparin	13655
4 % buffered paraformaldehyde	13676
4 %	13676
paraformaldehyde	13688
Spinal cord from the contused site	13706
Spinal cord	13706
the contused site	13723
a 10 % formalin solution for 2 h	13762
a 10 % formalin solution	13762
2 h	13790
paraffin	13807
4 μm sections	13829
The sections	13844
0.3 % H2O2 in methanol	13875
0.3 % H2O2	13875
methanol	13888
the endogenous peroxidase	13911
nonspecific staining	13942
3 % normal serum	13980
Primary antibodies	13997
NF	14031
mouse anti-Neurofilament SMI31	14035
1:1 000 ; Sternberger Monoclonals Inc. , Baltimore	14067
1:1 000	14067
Sternberger Monoclonals Inc. , Baltimore	14076
Sternberger Monoclonals Inc.	14076
Baltimore	14106
MD , USA	14117
1 % normal serum	14141
the tissue	14169
sections at 37 °C for 1 h and then at 4 °C overnight	14180
sections	14180
37 °C for 1 h	14192
37 °C	14192
1 h	14202
4 °C	14218
overnight	14223
Sections	14234
an appropriate	14263
secondary antibody	14291
1:200	14311
Vector Laboratories , Burlingame , CA , USA	14318
Vector Laboratories	14318
Burlingame	14339
CA	14351
USA	14355
ABC complex	14372
45 min at room temperature	14388
45 min	14388
room temperature	14398
Diaminobenzidine	14416
DAB-brown color	14434
Sigma Chemical Co. , St. Louis , MO , USA	14451
Sigma Chemical Co.	14451
St. Louis	14471
MO	14482
USA	14486
the chromatogen	14503
The sections	14520
hematoxylin	14558
alcohols	14592
The sections stained with normal serum	14615
The sections	14615
normal serum	14641
control	14668
Omission of primary antibodies	14677
Omission	14677
primary antibodies	14689
only weak , nonspecific labeling of the blood vessels	14720
only weak	14720
nonspecific labeling of the blood vessels	14731
nonspecific labeling	14731
the blood vessels	14755
Quantification of the proportional area at the center of the lesion at 40 ×	14774
Quantification	14774
the proportional area at the center of the lesion at 40 ×	14792
the proportional area	14792
the center of the lesion at 40 ×	14817
the center	14817
the lesion at 40 ×	14831
the lesion	14831
40 ×	14845
a computer-assisted digital image analysis system -LRB- MPIAS-500 -RRB-	14872
a computer-assisted digital image analysis system	14872
MPIAS-500	14923
the relative optical density threshold	14959
positive stained properties within a defined target area	15010
positive	15010
properties	15027
a defined target area	15045
FG-labeled neurons	15068
fluorescent microscope	15146
2.13 Statistical analysis Data	15170
histological analysis and the BBB scores	15215
histological analysis	15215
the BBB scores	15241
statistical differences	15274
animal groups using one-way ANOVA and Student-Newman-Keuls tests	15306
animal groups	15306
one-way ANOVA and Student-Newman-Keuls tests	15326
P	15372
0.05	15376
All data incorporated in the analysis	15423
All data	15423
the analysis	15448
the animals survived the entire study	15480
the animals	15480
the entire study	15501
3 Results Fig. 1 Human neuroblastoma cells	15520
3 Results	15520
1 Human neuroblastoma cells	15535
medium from olfactory ensheathing glia -LRB- OEG -RRB- cultures	15577
olfactory ensheathing glia	15589
OEG	15617
Moderate extensions of neurites	15632
Moderate extensions	15632
neurites	15655
human neuroblastoma cells	15683
medium from untransfected or pcDNA3 .1 -LRB- + -RRB-	15730
medium	15730
untransfected or pcDNA3 .1 -LRB- + -RRB-	15742
untransfected or pcDNA3 .1	15742
+	15768
transfected OEG -LRB- A , B -RRB-	15771
transfected OEG	15771
A , B	15788
A	15788
B	15791
Robust outgrowth of neurites from neuroblastoma cells -LRB- C -RRB-	15795
Robust outgrowth	15795
neurites from neuroblastoma cells -LRB- C -RRB-	15815
neurites	15815
neuroblastoma cells -LRB- C -RRB-	15829
neuroblastoma cells	15829
C	15850
suspected synapse connection -LRB- D -RRB-	15857
suspected synapse connection	15857
D	15887
medium from the OEG	15906
medium	15906
the OEG	15918
NT-3	15943
plasmid vector	15958
Scale bar , 8 μm .	15984
Scale bar	15984
8 μm	15995
Fig. 2 In vivo transgene expression .	16002
Fig. 2	16002
In vivo transgene expression	16009
Lane A	16039
Lane	16039
A	16044
untreated group ; Lane B : OEG group ; Lane C	16047
untreated group	16047
Lane B : OEG group	16064
Lane B	16064
OEG group	16072
Lane C	16083
pcDNA3	16091
+	16100
+ OEG group ; Lane D : pcDNA3	16102
+ OEG	16102
group ;	16107
group	16107
Lane D : pcDNA3	16114
Lane	16114
D	16119
pcDNA3	16122
1 -LRB- + -RRB- - NT3 + OEG group .	16130
1	16130
+	16132
NT3 + OEG group	16135
NT3	16135
OEG group	16139
The pcDNA3	16150
+	16163
- NT3-tansfected OEG group expressed high level of NT-3 mRNA	16165
- NT3-tansfected OEG group expressed high level of NT-3	16165
NT3-tansfected	16166
OEG group	16181
OEG	16181
expressed high level of NT-3	16191
expressed high level	16191
NT-3	16215
mRNA	16220
Fig. 3 -LRB- - -RRB- Fig. 4	16227
Fig. 3 -LRB- - -RRB-	16227
Fig. 3	16227
-	16235
Fig. 5 Basso Beattie Bresnahan	16251
-LRB- BBB -RRB- locomotor score -LRB- mean ± SD -RRB-	16282
-LRB- BBB -RRB- locomotor score	16282
BBB	16283
mean ± SD	16305
mean	16305
± SD	16309
rats in different groups	16317
rats	16317
different groups	16325
Rats that received pcDNA3 .1 -LRB- + -RRB- - NT3 transfected OEG revealed active	16343
Rats	16343
pcDNA3 .1	16362
+	16371
- NT3 transfected OEG revealed active	16373
- NT3 transfected OEG revealed	16373
NT3	16374
OEG revealed	16390
OEG	16390
active	16403
hindlimb movement	16422
six weeks	16440
injury	16462
The only OEG implantation and untreated rats	16470
The only OEG implantation	16470
untreated rats	16500
either paralysis or occasional uncoordinated hindlimb spasms	16525
paralysis	16532
occasional uncoordinated hindlimb spasms	16545
injury	16592
Differences between every two weeks	16600
Differences	16600
every two weeks	16620
post hoc means-corrected t-test -LRB- P < 0.05 -RRB-	16655
post hoc means-corrected t-test	16655
P < 0.05	16688
P	16688
< 0.05	16690
<	16690
0.05	16692
3.1 In vitro analysis	16700
transgenic neurotrophin expression Transfection	16725
purified OEG cultures with plasmid-liposome complex	16776
purified OEG cultures	16776
plasmid-liposome complex	16803
comparatively high levels of transgene expression	16840
comparatively high levels	16840
transgene expression	16869
many cells	16893
determined by in situ hybridization	16907
3 d after infection -LRB- data not shown -RRB-	16946
3 d	16946
infection	16956
data not shown	16967
data	16967
Transfection efficiency	16984
30 %	17019
fluorescence assay	17040
Numerous cells	17060
high levels of NT-3 mRNA	17085
high levels	17085
NT-3 mRNA	17100
signs of toxicity or cytopathological effects	17118
signs	17118
toxicity or cytopathological effects	17127
No staining for any of the transgenes	17165
No staining	17165
any of the transgenes	17181
any	17181
the transgenes	17188
untransfected OEGs	17219
control cultures	17253
hybridization	17279
sense probe	17298
Conditioned medium from transfeced OEG cultures	17311
Conditioned medium	17311
transfeced OEG cultures	17335
the presence of NT-3	17376
the presence	17376
NT-3	17392
an ELISA assay	17403
4 d	17418
transfection	17434
NT-3	17448
the medium samples	17475
n	17495
4	17499
control or pcDNA3 .1 -LRB- + -RRB-	17513
control or pcDNA3 .1	17513
+	17533
OEG cultures	17548
transfection	17568
pcDNA3 .1	17586
+	17595
- NT3 , ELISA analysis	17597
NT3 , ELISA	17598
NT3	17598
ELISA	17603
medium samples	17621
least -LRB- 21.7 ± 4.8 -RRB- ng	17653
21.7 ± 4.8	17660
21.7 ±	17660
4.8	17665
recombinant NT-3 was secreted from 1 ×	17676
recombinant NT-3	17676
1 ×	17711
105 cells per day	17713
105 cells	17713
day	17727
These results	17732
the time-point of implantation	17764
the time-point	17764
implantation	17782
high amounts of recombinant neurotrophin	17796
high amounts	17796
recombinant neurotrophin	17812
NT-3-transfected OEG as compared with controls	17856
NT-3-transfected OEG as	17856
controls	17894
Biological activity of plasmid-derived NT-3	17904
Biological activity	17904
plasmid-derived NT-3	17927
a coculture experiment	17968
this	17996
human neuroblastoma cells -LRB- n = 12 -RRB-	18002
human neuroblastoma cells	18002
n	18029
12	18033
medium	18056
OEG cultures	18068
the effect of transgenic neurotrophic factor production	18094
the effect	18094
transgenic neurotrophic factor production	18108
neurite outgrowth	18185
3 d	18206
the initial plating	18216
Moderate extensions of neurites	18237
Moderate extensions	18237
neurites	18260
human neuroblastoma cells	18288
medium from untransfected or pcDNA3 .1 -LRB- + -RRB-	18335
medium	18335
untransfected or pcDNA3 .1 -LRB- + -RRB-	18347
untransfected or pcDNA3 .1	18347
+	18373
transfected OEG -LRB- Fig. 1A , B -RRB-	18376
transfected OEG	18376
Fig. 1A , B	18393
Fig. 1A	18393
B	18402
No visible differences in radial neurite outgrowth	18406
No visible differences	18406
radial neurite outgrowth	18432
these groups	18479
plasmid vector transfection	18509
the growth supporting properties of OEG	18560
the growth	18560
properties of OEG	18582
properties	18582
OEG	18596
A robust outgrowth of neurites from neuroblastoma cells	18601
A robust outgrowth	18601
neurites from neuroblastoma cells	18623
neurites	18623
neuroblastoma cells	18637
medium from OEG transfected with a plasmid vector-encoding NT-3	18672
medium	18672
OEG transfected with a plasmid vector-encoding NT-3	18684
OEG	18684
a plasmid vector-encoding NT-3	18705
Fig. 1C	18747
These results	18757
plasmid vector-derived NT-3	18788
recombinant NT-3	18857
OEG	18902
3.2 In vivo analysis of transgene expression	18907
3.2 In vivo analysis	18907
3.2	18907
In vivo analysis	18911
transgene expression	18931
7 d	18955
implantation	18965
transgene expression in OEG implants	18979
transgene expression	18979
OEG implants	19003
RT-PCR	19032
The tissue from rats in pcDNA3 .1 -LRB- + -RRB- - NT3-tansfected OEG group	19040
The tissue	19040
rats in pcDNA3 .1 -LRB- + -RRB- - NT3-tansfected OEG group	19056
rats	19056
pcDNA3 .1 -LRB- + -RRB- - NT3-tansfected OEG group	19064
pcDNA3 .1	19064
+	19073
NT3-tansfected OEG group	19077
high levels of NT-3 mRNA -LRB- Fig. 2 -RRB-	19112
high levels	19112
NT-3 mRNA -LRB- Fig. 2 -RRB-	19127
NT-3 mRNA	19127
Fig. 2	19138
3.3 Axonal survival and regeneration	19147
3.3 Axonal survival	19147
regeneration	19171
axonal survival and regeneration	19196
NF immunoreactivity	19230
12 weeks	19266
The significantly more NF-positive axons	19288
the pcDNA3	19341
+	19354
NT3-tansfected OEG group	19357
pcDNA3 .1 -LRB- + -RRB- - transfected and untransfected	19390
pcDNA3 .1	19390
+	19399
OEG groups	19432
untreated group -LRB- Fig. 3 ; P < 0.05 -RRB-	19447
untreated group	19447
Fig. 3 ; P < 0.05	19464
Fig. 3	19464
P < 0.05	19472
P <	19472
P	19472
0.05	19476
The FG labeling	19483
retrograde transportation of regenerated fibers	19511
retrograde transportation	19511
regenerated fibers	19540
the glial scar	19568
the distal part of spinal cord	19599
the distal part	19599
spinal cord	19618
the lesion regions	19638
Some labeled neurons	19658
Some	19658
neurons	19671
the cervical spinal cord and some parts of the cerebrum	19696
the cervical spinal cord	19696
some parts of the cerebrum	19725
some parts	19725
the cerebrum	19739
cortex -LRB- Fig. 4 -RRB-	19763
cortex	19763
Fig. 4	19771
3.4 Functional recovery	19780
some of the rats	19819
some	19819
the rats	19827
cystitis or other infections	19846
the numbers of rats	19879
the numbers	19879
rats	19894
the 12th week after SCI were 10 in the pcDNA3	19914
the 12th week	19914
SCI	19934
10 in the pcDNA3	19943
10	19943
the pcDNA3	19949
+	19963
NT3-transfected OEG group , 9 in the untransfected OEG group	19966
NT3-transfected OEG group	19966
9 in the untransfected OEG group	19993
9	19993
the untransfected OEG group	19998
9 in the pcDNA3 .1 -LRB- + -RRB-	20027
9	20027
the pcDNA3 .1 -LRB- + -RRB-	20032
the pcDNA3 .1	20032
+	20045
transfected OEG group and 7	20048
transfected OEG group	20048
7	20074
untreated group	20079
Blind functional assessments and analyses	20096
Blind functional assessments	20096
analyses	20129
the BBB open field locomotion scale	20162
The rats	20199
either paralysis or durative uncoordinated hindlimb spasms	20228
paralysis	20235
durative uncoordinated hindlimb spasms	20248
Three weeks	20288
SCI	20306
initial paralysis	20311
the animals	20347
pcDNA3 .1 -LRB- + -RRB-	20374
pcDNA3 .1	20374
+	20383
NT3-transfected OEG -LRB- Fig. 5 -RRB-	20386
NT3-transfected OEG	20386
Fig. 5	20407
Six weeks	20416
SCI	20432
they	20437
extensive joint movement	20455
their hindlimbs	20483
their BBB score	20504
the other three groups -LRB- P < 0.05 -RRB-	20558
the other three groups	20558
P < 0.05	20582
P	20582
< 0.05	20584
<	20584
0.05	20586
The mean BBB scores at 12-week	20593
The mean BBB scores	20593
12-week	20616
12.50	20629
10.39	20636
10.22 and 3.78 , respectively	20643
10.22 and 3.78	20643
pcDNA3 .1 -LRB- + -RRB- - NT3 + OEG , OEG , pcDNA3 .1 -LRB- + -RRB- + OEG	20676
pcDNA3	20676
+	20685
- NT3 + OEG , OEG , pcDNA3 .1 -LRB- + -RRB- + OEG	20687
- NT3 + OEG , OEG , pcDNA3 .1	20687
NT3 + OEG	20688
NT3	20688
OEG	20692
OEG , pcDNA3 .1	20696
OEG	20696
pcDNA3 .1	20701
+ OEG	20712
Rats	20740
the pcDNA3	20748
+	20761
- NT3-transfected OEG group had better performances compared with those in	20763
NT3-transfected OEG	20764
group had better performances compared	20784
group	20784
better performances	20794
those	20828
other groups	20837
P < 0.05	20851
P	20851
< 0.05	20853
<	20853
0.05	20855
The pcDNA3 .1 -LRB- + -RRB-	20862
The pcDNA3 .1	20862
+	20875
transfected OEG group and the untransfected OEG group	20878
transfected OEG group	20878
the untransfected OEG group	20904
no significantly difference	20936
4 Discussion	20967
OEG implantation	20993
ex vivo plasmid vector-mediated NT-3 gene transfer	21015
ex vivo plasmid	21015
vector-mediated NT-3 gene transfer	21031
we	21067
the following results	21083
this study	21108
OEG	21124
plasmid , a non-viral vector , mediated with cationic liposome	21164
plasmid	21164
a non-viral vector	21173
cationic liposome	21207
OEG	21239
both ex vivo	21255
the recombinant NT-3 protein	21292
biological activity	21326
The NT3-transfected OEG implants	21351
recovery of hindlimb function	21393
recovery	21393
hindlimb function	21405
behavioral testing	21440
Quantitative histological	21464
the NT3-transfected OEG implants	21502
the axonal regeneration	21547
injured spinal cord	21581
genetic modified OEG	21613
the injured spinal cord	21645
simple OEG	21681
many problems	21702
we	21733
that OEG combined with gene therapy	21745
that OEG	21745
gene therapy	21768
a promising strategy	21784
Gene therapy	21806
delivery of nucleic acids	21839
delivery	21839
nucleic acids	21851
patients via a vector for therapeutic purposes	21868
patients	21868
a vector for therapeutic purposes	21881
a vector	21881
therapeutic purposes	21894
This	21916
a promising therapeutic method	21924
currently enormous failure of clinical trials	21962
currently enormous failure	21962
clinical trials	21992
The primary reason for current failure and frustration	22009
The primary reason	22009
current failure and frustration	22032
no adequate vectors	22072
therapeutic nucleic acids	22117
their desired site of action	22146
their desired site	22146
action	22168
the chosen cells	22178
There	22196
two kinds	22206
vectors , viral and non-viral vector system	22219
vectors	22219
viral	22228
non-viral vector system	22238
gene delivery	22272
Synthetic non-viral vector systems	22287
many advantages compared with viral systems	22327
many advantages	22327
viral systems	22357
significantly lower toxicity/immunogenicity and potential for oncogenicity	22382
significantly lower toxicity/immunogenicity	22382
potential for oncogenicity	22430
potential	22430
oncogenicity	22444
size independent delivery	22458
nucleic acids -LRB- from oligonucleotides to artificial chromosomes -RRB-	22487
nucleic acids	22487
oligonucleotides to artificial chromosomes	22507
oligonucleotides	22507
artificial chromosomes	22527
simpler quality control	22552
substantially easier pharmaceutical	22581
regulatory requirements -LSB- 19 -RSB-	22621
regulatory requirements	22621
19 -RSB-	22645
public alarm	22661
the toxic side effects of virus	22692
the toxic side effects	22692
virus	22718
these significant advantages	22746
Basic clinical confidence in non-viral vectors	22776
Basic clinical confidence	22776
non-viral vectors	22805
the various advantages	22838
inherent in synthetic non-viral vector systems	22874
synthetic non-viral vector	22886
substantial clinical uptake	22935
the science and technology of these vector systems	22968
the science and technology	22968
these vector systems	22998
routine clinical use	23052
our original proof of present study	23077
our original proof	23077
present study	23099
we	23114
cationic liposome	23128
delivery of recombinant NT-3 cDNA	23160
delivery	23160
recombinant NT-3 cDNA	23172
OEG	23197
production	23223
therapeutic levels of functional NT-3 protein in injured spinal cord	23237
therapeutic levels	23237
functional NT-3 protein in injured spinal cord	23259
functional NT-3 protein	23259
injured spinal cord	23286
Neurotrophins	23307
biological effects	23327
their specific combination with the receptor	23359
their specific combination	23359
the receptor	23391
A kind of neurotrophin	23405
A kind	23405
neurotrophin	23415
some specific neurites	23444
SCI of mammalian	23474
SCI	23474
mammalian	23481
the recovery	23492
corticospinal tract -LRB- CST -RRB- and main sensory pathway	23508
corticospinal tract -LRB- CST -RRB-	23508
corticospinal tract	23508
CST	23529
main sensory pathway	23538
NT-3 receptors	23566
NT-3	23621
the appropriate candidate -LSB- 20 -RSB-	23629
the appropriate candidate	23629
20 -RSB-	23655
Many researches	23660
Many	23660
NT-3	23692
the survival of sensory , motor and sympathetic neurons	23710
the survival	23710
sensory , motor and sympathetic neurons	23726
neuronal apoptosis	23774
SCI	23799
the axonal regeneration	23814
the ability of promoting axonal regeneration	23842
the ability	23842
axonal regeneration	23867
NT-3	23888
nerve growth factor	23900
NGF	23921
brain-derived neurotrophic factor -LRB- BDNF -RRB- -LSB- 21 -RSB-	23929
brain-derived neurotrophic factor -LRB- BDNF -RRB-	23929
brain-derived neurotrophic factor	23929
BDNF	23964
21 -RSB-	23970
date	23978
a number of axon populations	23984
a number	23984
axon populations	23996
OEG implants in different injury models	24049
OEG implants	24049
different injury models	24065
sensory axons	24100
the dorsal root axons -LSB- 21,22	24117
the dorsal root axons	24117
21,22	24139
serotonergic axons -LSB- 8,9,24,25	24157
serotonergic axons	24157
8,9,24,25	24176
CST axons -LSB- 7,8 -RSB-	24191
CST axons	24191
7,8 -RSB-	24201
Some controversy	24207
the regenerative response of the CST	24238
the regenerative response	24238
the CST	24267
others	24283
OEG	24301
the proximal injury site -LSB- 26 -RSB-	24338
the proximal injury site	24338
26 -RSB-	24363
the present study	24371
a significant axonal regeneration and better recovery of locomotion function	24390
a significant axonal regeneration	24390
better recovery of locomotion function	24428
better recovery	24428
locomotion function	24447
implantation of OEG transfected with NT-3	24483
implantation	24483
OEG transfected with NT-3	24499
OEG	24499
NT-3	24520
plasmid	24535
no fully recovery of locomotion	24548
no fully recovery	24548
locomotion	24569
it	24600
no sufficient NT-3 was produced by the OEG transfected with non-viral vector	24613
no sufficient NT-3	24613
the OEG transfected with non-viral vector	24648
the OEG	24648
non-viral vector	24673
we	24695
no fully recovery of locomotion	24722
no fully recovery	24722
locomotion	24743
previous study using viral vector -LSB- 16,27 -RSB-	24777
previous study	24777
viral vector -LSB- 16,27 -RSB-	24798
viral vector	24798
16,27 -RSB-	24811
we	24822
the repair of injured spinal cord	24831
the repair	24831
injured spinal cord	24845
the balance between promoter and inhibitor	24876
the balance	24876
promoter and inhibitor	24896
the single use	24923
promoter such as OEG or neurotrophin without dealing with inhibitor such as Nogo	24941
promoter	24941
OEG or neurotrophin without dealing with inhibitor such as Nogo	24958
OEG or neurotrophin	24958
inhibitor such as Nogo	24999
inhibitor	24999
Nogo	25017
nerve regeneration	25071
It	25091
more insight	25127
overall requirements of injured spinal cord	25143
overall requirements	25143
injured spinal cord	25167
Extended knowledge	25188
both promotion factors and inhibition ones	25210
regeneration of nerve tracts	25265
regeneration	25265
nerve tracts	25281
the development of more optimal microenvironment	25305
the development	25305
more optimal microenvironment	25324
The combination of neural transplantation and neurotrophin delivery	25355
The combination	25355
neural transplantation and neurotrophin delivery	25374
a promising strategy	25438
regeneration and functional recovery	25470
spinal cord injury -LSB- 28,29 -RSB-	25513
spinal cord injury	25513
28,29 -RSB-	25532
We	25540
ex vivo transfection of OEG with NT-3-encoding plasmid vectors	25560
ex vivo transfection	25560
OEG with NT-3-encoding plasmid vectors	25584
OEG	25584
NT-3-encoding plasmid vectors	25593
axonal regeneration	25654
2	25676
the growth-promoting properties of these cells	25687
the growth-promoting properties	25687
these cells	25722
-LRB- 3 -RRB- improve functional recovery after implantation	25739
improve functional recovery	25743
implantation	25777
A limitation of only neurotrophintransfected OEG implants	25791
A limitation	25791
only neurotrophintransfected OEG implants	25807
they	25857
inhibitors	25881
another important factor affecting repair of injured spinal cord	25911
another important factor	25911
repair of injured spinal cord	25946
repair	25946
injured spinal cord	25956
Combination of promoter and inhibitor antagonist	25977
Combination	25977
promoter and inhibitor antagonist	25992
the results	26054
hope	26083
the use of these modified cells in both acute and chronic SCI models	26092
the use	26092
these modified cells in both acute and chronic SCI models	26103
these modified cells	26103
both acute and chronic SCI models	26127
